JAK2 and myeloproliferative neoplasm: Thus, these results suggest that bone marrow stromal derived factors play a significant role in protecting Jak2-V617F positive cells from Ruxolitinib-induced cell death, thereby highlighting the role of the bone marrow micro-environment not only in the MPN disease pathogenesis, but also in resistance to subsequent Jak2 targeted therapies.